Coronavirus company news summary - Empowered Diagnostics receives CE mark for CovClear Covid-19 rapid antigen test - Sense raises $50m Series B funding to launch Covid-19 molecular test

Empowered Diagnostics has received the CE Mark approval for its CovClear Covid-19 rapid antigen test. CovClear is a lower-cavity nasal swab test that can identify Covid-19 infection within two days of exposure. Quick and easy to use, the test delivers results with 99.7% accuracy, 98.5% sensitivity, and 100% specificity.

QIAGEN has announced the launch of the artus SARS-CoV-2 Prep&Amp UM kit, which uses a liquid sample preparation technology to increase and simplify Covid-19 testing throughput. The test kit is CE-IVD registered, and is therefore allowed to be used in the European Union (EU) and other markets. The company has applied for emergency use authorisation (EUA) by the US Food and Drug Administration (FDA), for its commercialisation and use in the US.

Sense Biodetection has raised a $50m Series B investment to accelerate the commercialisation of its Veros Covid-19 product and a portfolio of instrument-free rapid molecular tests. The Veros platform allows the use of proprietary rapid molecular amplification technology for detecting many deadly and expensive diseases.